961.17(1m)(1m)
The controlled substances board shall add a substance to schedule III upon finding that:
961.17(1m)(a)
(a) The substance has a potential for abuse less than the substances included in schedules I and II;
961.17(1m)(b)
(b) The substance has currently accepted medical use in treatment in the United States; and
961.17(1m)(c)
(c) Abuse of the substance may lead to moderate or low physical dependence or high psychological dependence.
961.17(2m)
(2m) The controlled substances board may add a substance to schedule III without making the findings required under sub.
(1m) if the substance is controlled under schedule III of
21 USC 812 (c) by a federal agency as the result of an international treaty, convention or protocol.
961.17 History
History: 1971 c. 219;
1995 a. 448 ss.
179,
180,
474; Stats. 1995 s. 961.17.
961.18
961.18
Schedule III. Unless specifically excepted by state or federal law or regulation or more specifically included in another schedule, the following controlled substances are listed in schedule III:
961.18(2m)
(2m) Stimulants. Any material, compound, mixture, or preparation which contains any quantity of any of the following substances having a stimulant effect on the central nervous system, including any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation:
961.18(3)
(3) Depressants. Any material, compound, mixture or preparation which contains any quantity of any of the following substances having a depressant effect on the central nervous system, including any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation:
961.18(3)(a)
(a) Any substance which contains a derivative of barbituric acid;
961.18(3)(m)
(m) Any compound, mixture, or preparation containing any of the following drugs and one or more other active medicinal ingredients not included in any schedule:
961.18(3)(n)
(n) Any of the following drugs in suppository dosage form approved by the federal food and drug administration for marketing only as a suppository: